MedTrace Logo

Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

NCT07307131 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-01-02

No results posted yet for this study

Summary

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Conditions

  • Cutaneous Warts
  • Human Papilloma Virus (HPV)

Interventions

DRUG

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

DRUG

Intralesional polidocanol 2%

Group B (Active Comparator): Intralesional polidocanol 2%

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ghada Shams, MD · Benha University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2025-03-01
Completion
2025-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07307131 on ClinicalTrials.gov